All In Biotech

NDA 211746 · Glenmark Speclt

Ryaltris

Mometasone Furoate, Olopatadine Hydrochloride · Nasal

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jan 13, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

251

94 Phase 3, 12 recruiting

FAERS reports

2,035

299 serious, 14 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 21, 2026.

RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients of age 6 years and older. RYALTRIS is a combination of olopatadine, a histamine-1 (H1)-receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. ( 1 )

Mechanism: RYALTRIS contains both olopatadine hydrochloride and mometasone furoate. The mechanisms of action described below for the individual components apply to RYALTRIS. Olopatadine Hydrochloride Olopatadine is a histamine-1 (H1) receptor inhibitor. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans. Mometasone Furoate Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • RYALTRIS · MOMETASONE FUROATE 0.025MG/SPRAY; OLOPATADINE HYDROCHLORIDE 0.665MG/SPRAY · SPRAY, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mometasone Furoate" as an intervention, any sponsor and status, largest first.

All 251 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device delivery system issue705
  • product use in unapproved indication612
  • drug dose omission by device520
  • product use issue431
  • drug ineffective198
  • device issue160
  • wrong technique in device usage process144
  • device occlusion134
  • epistaxis125
  • condition aggravated73
  • product tampering71
  • device defective64

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
20205
20223
2023258
2024658
2025285
2026825

Recalls

1 FDA enforcement reports for this application.

  • Sep 24, 2024 · Class II · Ongoing

    Defective Delivery System: The dip tube is clogged causing the spray not to work.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ryaltris (Olopatadine HCl/Mometasone)

2024 spending

$3.0M

Beneficiaries

4,904

9,849 claims

Per beneficiary

$604

$8.34 per unit

View as table
YearSpending
2020$0
2021$0
2022$15,299
2023$1,046,225
2024$2,962,469

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 420 on PubMed

Sponsor: Glenmark Speclt

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.